Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

11004638001

Roche

Chymostatin

Synonyme(s) :

Chymostatin, N-(Nα-Carbonyl-Cpd-X-Phe-al)-Phe (Cpd = capreomycidine) (capreomycidine = [S,S]-α-(2-Iminohexahydro-4-pyrimidyl)glycine)

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Numéro CAS:
Numéro MDL:
Code UNSPSC :
12352204
ID de substance PubChem :

Forme

powder

Niveau de qualité

Poids mol.

Mr = 607.71

Conditionnement

pkg of 10 mg

Fabricant/nom de marque

Roche

Pf

205 °C

Solubilité

acetic acid: soluble 20 mg/mL

Température de stockage

2-8°C

Chaîne SMILES 

OC(C(NC(NC(C1NC(NCC1)=N)C([F,Cl,Br,I]C)=O)=O)CC2=CC=CC=C2)=O

Clé InChI

MRXDGVXSWIXTQL-HYHFHBMOSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Chymostatin is a mixture of three components, A, B, and C. The component A being N-[((S)-1-carboxy-2-phenylethyl)-carbamoyl]-α-[2-iminohexahydro-4(S)-pyrimidyl]-L-glycyl-L-leucyl-phenylalaninal. The other two components B and C differ in that the L-leucyl residue is substituted by L-valine and L-isoleucine, respectively.

Application

Chymostatin is a specific inhibitor of α-, β-, γ-, and δ-chymotrypsin.

Actions biochimiques/physiologiques

Chymostatin is a strong inhibitor of many proteases, including chymotrypsin, papain, chymotrypsin-like serine proteinases, chymases, and lysosomal cysteine proteinases such as cathepsins A,B,C, B, H, and L. It weakly inhibits human leucocyte elastase. It is effective at a final concentration of 100 to 200 μg/ml (10 to 100 μM). Chymostatin is often included in protease inhibitor cocktails used with plant extracts.

Qualité

Performance tested.

Variante de formule

C31H41N7O6

Notes préparatoires

Working concentration: 6 to 60 μg/ml (10 to 100 μM)
1 U chymotrypsin is inhibited to 49% of the original activity by 1.8 μg of chymostatin.
Thin-layer chromatography: butanol/methanol/H2O = 4 / 1 / 2
Working solution: Soluble in glacial acetic acid or DMSO to 20 mg/ml. Sparingly soluble in water, methanol, or ethanol. Insoluble in ethyl acetate, petroleum and ethyl ethers, hexane, or chloroform (CHCl3).
It is recommended to dissolve the inhibitor in 1% acetic acid in higher concentration and to adjust the concentration wanted with phosphate buffer, 0.05 M, pH 7.0, which is common for chymotrypsin assay.
CAUTION: DMSO (Dimethyl sulfoxide) will permeate the skin, carrying solubilized protease inhibitors. Always wear appropriate protection for eyes, skin, etc.
Storage conditions (working solution): -15 to -25 °C
Dilute solutions should be stored frozen in aliquots at -15 to -25 °C and are stable for approximately one month. Avoid repeated freezing. Growth of microorganisms should be avoided as proteases from microbial origin may hydrolyze the peptides.
Solubility testing in glacial acetic acid at 10 mg/ml yields a clear solution, which is usually colorless, but can be yellow in appearance. It is reportedly also soluble in DMSO; only slightly soluble in water and short-chain alcohols; insoluble in ethyl acetate, butyl acetate, ether, hexane, and petroleum ether. Stock solutions (10 mM) can be prepared in DMSO and are stable for months at -20 °C. Stock solutions can also be made in 0.1 M HCl. Dilute solutions (10-100 μM) are only stable for several hours, due to oxidation of the terminal aldehyde.

Autres remarques

For life science research only. Not for use in diagnostic procedures.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

The structure of chymostatin, a chymotrypsin inhibitor.
K Tatsuta et al.
The Journal of antibiotics, 26(11), 625-646 (1973-11-01)
Verena van der Heide et al.
Cell reports, 38(11), 110508-110508 (2022-03-06)
Concerns that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), may cause new-onset diabetes persist in an evolving research landscape, and precise risk assessment is hampered by, at times, conflicting evidence.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique